Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   35891   clinical trials with a EudraCT protocol, of which   5892   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-001956-31
    Sponsor's Protocol Code Number:2015-001956-31
    National Competent Authority:Denmark - DHMA
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2015-06-10
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedDenmark - DHMA
    A.2EudraCT number2015-001956-31
    A.3Full title of the trial
    Direct acting antiviral therapy of hepatitis C in Denmark: treatment response, adverse events and resistance associated variants
    Behandling af hepatitis C med direkte virkende antivirale præparater i Danmark: behandlingsrespons, bivirkninger, og udvikling af viral resistens
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Direct acting antiviral therapy of hepatitis C in Denmark: treatment response, adverse events and resistance associated variants
    Behandling af hepatitis C med direkte virkende antivirale præparater i Danmark: behandlingsrespons, bivirkninger, og udvikling af viral resistens
    A.4.1Sponsor's protocol code number2015-001956-31
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorDepartment of Infectious Diseases, Copenhagen University Hospital, Hvidovre.
    B.1.3.4CountryDenmark
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportThe danish database for hepatitis B and C
    B.4.2CountryDenmark
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationDepartment of Infectious Diseases, Copenhagen University Hospital, Hvidovre.
    B.5.2Functional name of contact pointNina Weis
    B.5.3 Address:
    B.5.3.1Street AddressKettegaard Alle 30
    B.5.3.2Town/ cityHvidovre
    B.5.3.3Post code2650
    B.5.3.4CountryDenmark
    B.5.4Telephone number004538623514
    B.5.6E-mailninaweis@dadlnet.dk
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Harvoni
    D.2.1.1.2Name of the Marketing Authorisation holderGilead Sciences International Ltd.
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNsofosbuvir
    D.3.9.1CAS number 1190307-88-0
    D.3.9.3Other descriptive nameSOFOSBUVIR
    D.3.9.4EV Substance CodeSUB121170
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number400
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLedipasvir
    D.3.9.1CAS number 1256388-51-8
    D.3.9.3Other descriptive nameLEDIPASVIR
    D.3.9.4EV Substance CodeSUB120165
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number90
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Sovaldi
    D.2.1.1.2Name of the Marketing Authorisation holderGilead Sciences International Ltd.
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSofosbuvir
    D.3.9.1CAS number 1190307-88-0
    D.3.9.3Other descriptive nameSOFOSBUVIR
    D.3.9.4EV Substance CodeSUB121170
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number400
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Viekirax PAK
    D.2.1.1.2Name of the Marketing Authorisation holderAbbVie Ltd
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPARITAPREVIR
    D.3.9.4EV Substance CodeSUB166312
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number75
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNOmbitasvir
    D.3.9.3Other descriptive nameOMBITASVIR
    D.3.9.4EV Substance CodeSUB131058
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number12.5
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRITONAVIR
    D.3.9.1CAS number 155213-67-5
    D.3.9.4EV Substance CodeSUB10342MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDasabuvir
    D.3.9.3Other descriptive nameDASABUVIR
    D.3.9.4EV Substance CodeSUB131059
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number250
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Daklinza
    D.2.1.1.2Name of the Marketing Authorisation holderBristol-Myers Squibb Pharma EEIG
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDaclatasvir
    D.3.9.1CAS number 1009119-64-5
    D.3.9.3Other descriptive nameDACLATASVIR
    D.3.9.4EV Substance CodeSUB75341
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number60
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Rebetol
    D.2.1.1.2Name of the Marketing Authorisation holderMerck Sharp & Dohme Limited
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNribavirin
    D.3.9.3Other descriptive nameRIBAVIRIN
    D.3.9.4EV Substance CodeSUB10297MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number800 to 1400
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 6
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Epclusa
    D.2.1.1.2Name of the Marketing Authorisation holderGilead sciences
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEpclusa
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNVELPATASVIR
    D.3.9.4EV Substance CodeSUB180213
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100 to 100
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 1190307-88-0
    D.3.9.3Other descriptive nameSOFOSBUVIR
    D.3.9.4EV Substance CodeSUB121170
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number400 to 400
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Patients with chronic hepatitis C
    Patienter med kronisk hepatitis C
    E.1.1.1Medical condition in easily understood language
    Patients with a chronic liver diasease caused by a virus called hepatitis C virus.
    Patienter med kronisk leverbetændelse type C.
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.1
    E.1.2Level LLT
    E.1.2Classification code 10074391
    E.1.2Term Chronic hepatitis C virus genotype 1
    E.1.2System Organ Class 100000004862
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To study the rate of adverse events and sustanied viral response in a randomized study of patients with chronic hepatitis C, genotype 1 patients, treated for 12 weeks with Viekira PAK® and ribavirin versus Harvoni® and ribavirin. Compare the adverse events- and sustanied viral response rates between the two groups of patients in each treatment arm in relation to demographic, biological and genetic factors.
    Del 1
    Vi ønsker at undersøge hyppigheden af bivirkninger af patienter med kronisk hepatitis C, genotype 1, randomiseret til behandling i 12 uger med Viekira PAK® og ribavirin versus Harvoni® og ribavirin.

    Vi ønsker at sammenligne hyppigheden af bivirkninger og helbredelses raten mellem de to grupper af patienter i hver behandlingsarm i forhold til demografisk data samt biologiske og genetiske faktorer.

    E.2.2Secondary objectives of the trial
    To investigate, by population sequencing for resistance associated varients, hepatitis C virus isolated from all patients who fail treatment in the randomised study described above both at baseline and post-treatment failure.

    Examine the effect of sofosbuvir/daclatasvir/ribavirin or sofosbuvir/velpatasvir with and without ribavirin for 12 weeks on the hepatic venous pressure gradient, systemic blood pressure, metabolic function of the liver and inflammatory cells in patients with chronic hepatitis C, genotype 3 and liver cirrhosis.

    To study if there is a change in perfusion of the heart and calcium score analyzed by heart - rubidium PET/CT scan, after treatment with direct acting antivirals for 8, 12 or 24 weeks in patients with chronic hepatitis C, genotype 1 or 3.
    Undersøgelse for viral resistens evalueret ved hjælp af populations sekventering af hepatitis C virus genomet hos patienter i forsøg 1 del 1 med behandlingssvigt.

    Vi ønsker at undersøge effekten af behandling med sofosbuvir /daclatasvir / ribavirin eller sofosbuvir/velpatasvir med og yden ribavirin i 12 uger på betændelsesceller (sCD163), blodtrykket i leveren, det systemiske blodtryk og leverfunktionen hos patienter med kronisk hepatitis C, genotype 3 og levercirrose.

    Vi ønsker at undersøge med hjerte-rubidium-PET, om der ses en ændring i hjertets perfusion og ved hjerte-CT om calciumscore ændres efter behandling med direkte virkende antivirale præparater i 8, 12 eller 24 uger hos patienter med kronisk hepatitis C, genotype 1 eller 3.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Patients of both sexes between 18-70 years
    • Patients are followed at one of the 18 departments affiliated with DANHEP, diagnosed with chronic HCV infection (verified by real-time PCR as the presence of HCV RNA in two blood samples taken 6 months apart).
    • Treatment-naïve or previous treatment with pegylated interferon / ribavirin or discontinuing treatment with pegylated interferon / ribavirin / telaprevir / boceprevir due to side effects.
    • Treatment demanding chronic hepatitis C virus infection.
    • Liver biopsy or Fibroscanning showing moderate to severe fibrosis (Metavir ≥F2 score) or cirrhosis. Liver fibrosis or cirrhosis examined by liver biopsy ranked by the Danish scoring system based on the Metavir scoring system, where stage F2 indicate moderate fibrosis stage F3; severe fibrosis and stage F4; cirrhosis. If the diagnosis is made with Fibroscanning; values> 7 kPa and <17kPa indicate moderate to severe fibrosis and values ≥17 kPa indicate cirrhosis.
    - Clinically diagnosed cirrhosis in the absence of liver biopsy or Fibroscanning, defined as overt cirrhosis at ultrasound (+/- spleen enlargement), low platelet count ≤110 * 109 cells / L, PT≤75 / INR> 1.7 (increased clotting of the blood) , serum albumin <6g / L or the presence of complications: ascites confirmed by ultrasound, esophageal varices diagnosed by gastroscopy or hepatic encephalopathy.
    • Infected with genotype 1 or genotype 3.
    • Women of childbearing potential must use effective contraception defined as copper or progesten spiral and condom must be used by partner throughout the treatment period.
    • Men who are treated in the trial must use condoms throughout treatment and for at least 7 months after completion of treatment.
    • Must be able to read and understand Danish.
    • Must be able to sign informed consent.
    • patients co-infected with HIV must be in anti-viral therapy.
    • Patienter af begge køn mellem 18-70 år
    • Patienter som følges på en af de 18 afdelinger der er tilknyttet DANHEP, diagnosticeret med kronisk HCV infektion (verificeret ved real-time PCR som tilstedeværelsen af HCV-RNA i 2 blodprøver taget med 6 måneders mellemrum).
    • Behandlings-naive eller tidligere behandling med PEGINF/RBV eller afbrudt behandling med pegyleret interferon/ribavirin/telaprevir/boceprevir pga. bivirkninger.
    • Behandlingskrævende kronisk hepatitis C virus infektion.
    • Lever biopsi eller Fibroscanning visende moderate til svær fibrose (Metavir ≥F2 score) eller cirrose. Lever fibrose eller cirrose undersøgt ved lever biopsi klassificeret efter det Danske score system baseret på Metavir scoring systemet, hvor stadie F2 indikere moderat fibrose, stadie F3; svær fibrose og stadie F4; cirrose. Hvis diagnosen er stillet med Fibroscanning; værdier >7 kPa og < 17kPa indikere moderat til svær fibrose og værdier ≥17 kPa indikere cirrose.
    • Klinisk diagnosticeret cirrose hvis der ikke foreligger leverbiopsi eller Fibroscanning, defineret som åbenlys cirrose ved ultralydsscanning (+/- milt forstørrelse), nedsat antal blodplader ≤110*109 celler/L, PT≤75/ INR>1.7 (forøget størkningstid af blodet), serum albumin < 6g/L eller tilstedeværelse af komplikationer: ascites konfirmeret ved ultralydsscanning, øsofagus varicer diagnosticeret ved gastroskopi eller hepatisk encephalopati.
    • Inficeret med genotype 1 eller genotype 3.
    • Kvinder i den fødedygtige alder skal benytte sikker prævention defineret som kobber eller gestagen spiral og kondom skal benyttes af partner i hele behandlingsperioden.
    • Mænd der behandles i forsøget skal anvende kondom under hele behandlingsforløbet samt i minimum 7 måneder efter afsluttet behandling.
    • Skal kunne læse og forstå dansk.
    • Skal kunne underskrive informeret samtykke.
    • Patienter co-inficeret med HIV skal være i anti-viral behandling.
    E.4Principal exclusion criteria
    Hypersensitivity to any of the ingredients in the medicine.
    • Severe untreated psychiatric illness which the investigator believe may affect treatment.
    • Severe mental illness; schizophrenia, psychosis, bipolar disorder, post-traumatic stress disorder, mania.
    • Current alcohol (> 25 objects weekly), intravenous drug or other drug abuse.
    • Decompensated cirrhosis.
    • Diagnosed with hepatocellular carcinoma or are being investigated for this.
    • Severe heart failure NYHA class III and IV
    • Previous stroke, TIA or AMI.
    • Severe angina pectoris, cardiomyopathy, pulmonary hypertension, uncontrolled hypertension or significant arrhythmia diagnosed by ECG.
    • Severe chronic lung disease; COPD, pulmonary fibrosis or sarcoidosis defined as; GOLD stage 3: FEV1 / FVC <0.7 and FEV1 between 30-50% predicted and GOLD stage 4: FEV1 / FVC <0.7 and FEV1 between the 30% predicted.
    • Myelodysplastic diseases.
    • Organ transplantation (except from hair or cornea)
    • Active cancer or diagnosed with cancer (other than basal cell skin cancer) within the past 5 years.
    • Autoimmune liver disease.
    • Haemoglobinopathies; sickle cell anemia and thalassemia.
    • Neutropenia <1.5 x 103 l
    • Thrombocytopenia <50 x 103 ul
    • Renal impairment (GFR <50 ml / min., Including hemodialysis)
    • thyroid disease that is not controlled by conventional therapy.
    • Insufficient treated epilepsy.
    • Pregnancy / lactation.
    • Severe untreated anemia, hemoglobin ≤ 5 mmol / l.
    • Treatment with carbamazepine, phenytoin, rifabutin, rifampicin, herbal preparations containing St. John's wort and modafinil.
    • Insufficient treated severe diabetes, HbA1c> 8.5%.
    • Severe hepatic impairment (Child-Pugh C).
    • The use of contraceptives with ethinylestradiol
    • Treatment with CYP3A4 substrates; Alfuzosin, amiodarone, Atorvastatin, ergotamine, Fusidic acid, Lovastatin, Oral midazolam, pimozide, Quetiapine, Salmeterol, Sildenafil against pulmonary arterial hypertension, Simvastatin, Triazolam, Rosuvastatin.
    • Treatment with potent CYP3A4 inducers or other enzyme inducers; Efavirenz, etravirine, Enzalutamid, Mitotane, Nevirapine, Phenobarbital.
    • The treatment with strong CYP3A4 inhibitors; Clarithromycin, Cobicistat, itraconazole, lopinavir / ritonavir, posaconazole, voriconazole.
    • Treatment with strong CYP2C8 inhibitors; Gemfibrozil.
    • Allergi overfor et af indholdsstofferne i medicinen.
    • Svær ubehandlet psykiatrisk sygdom som i følge investigator kan påvirke behandlingen.
    • Svær psykisk sygdom; skizofreni, psykose, bipolær sygdom, post-traumatisk stress syndrom, mani.
    • Nuværende alkohol (> 25 genstande ugentligt), intravenøst stof eller narkotika misbrug.
    • Dekompenseret cirrose.
    • Er kendt med hepatocellulær carcinoma eller er under udredning for dette.
    • Svær hjertesygdom NYHA klasse III og IV,
    • Tidligere blodprop i hjernen, TCI eller AMI.
    • Svær angina pectoris, kardiomyopati, pulmonal hypertension, ukontrolleret hypertension eller signifikant arythmi diagnosticeret ved EKG.
    • Svær kronisk lungesygdom; KOL, pulmonal fibrose eller sarkoidose defineret som GOLD stadium 3: FEV1/FVC < 0,7 og FEV1 mellem 30-50 % af forventet værdi og GOLD stadium 4: FEV1/FVC < 0,7 og FEV1 mellemunder 30 % af forventet værdi.
    • Myelodysplastiske sygdomme.
    • Organtransplanteret (udover hår eller hornhinde)
    • Aktiv cancer eller diagnosticeret med cancer (udover basalcelle hud cancer) indenfor de sidste 5 år.
    • Autoimmun leversygdom.
    • Hæmoglobinopatier; seglcelleanæmi og thalassæmi.
    • Neutropeni <1.5 x 103 µL
    • Trombocytopeni <50 x 103 µL
    • Nedsat nyrefunktion (GFR < 50 ml/min., herunder hæmodialyse)
    • Thyroideasygdom, der ikke er under kontrol med konventionel behandling.
    • Insufficient behandlet epilepsi.
    • Graviditet/amning.
    • Svær ubehandlet anæmi (blodmangel), hæmoglobin ≤ 5 mmol/l.
    • Behandling med carbamazepin, phenytoin, rifabutin, rifampicin, naturlægemidler med perikon og modafinil.
    • Insufficient behandlet svær diabetes, HbA1c >8.5%.
    • Stærkt nedsat leverfunktion (Child-Pugh C).
    • Indtagelse af præventionsmidler med ethinylestradiol
    • Behandling med CYP3A4-substrater; Alfuzosin, Amiodaron, Atorvastatin, Ergotamin, Fusidinsyre, Lovastatin, Oralt midazolam, Pimozid, Quetiapin, Salmeterol, Sildenafil mod pulmonal arteriel hypertension, Simvastatin, Triazolam, Rosuvastatin.
    • Behandling med kraftige CYP3A4-induktorer eller andre enzyminduktorer; Efavirenz, Etravirin, Enzalutamid, Mitotan, Nevirapin, Phenobarbital.
    • Behandling med kraftige CYP3A4-inhibitorer; Clarithromycin, Cobicistat, Itraconazol, Lopinavir/ritonavir, Posaconazol, Voriconazol.
    • Behandling med kraftige CYP2C8-inhibitorer; Gemfibrozil.
    E.5 End points
    E.5.1Primary end point(s)
    The frequency of side effects seen when treated for 12 weeks with Viekira PAK + Exviera® and ribavirin versus Harvoni® and ribavirin in patients with chronic hepatitis C infected with genotype 1.
    Hyppigheden af bivirkninger ved behandling i 12 uger med Viekira PAK®+Exviera® og ribavirin versus Harvoni® og ribavirin hos patienter med kronisk hepatitis C inficeret med genotype 1.
    E.5.1.1Timepoint(s) of evaluation of this end point
    After end of treatment of the last included patient in the trial.
    Når alle inkluderede patienter har færdiggjort behandlingen.
    E.5.2Secondary end point(s)
    Treatment response defined as following:
    - Sustained virological response (SVR): negative HCV RNA 12 weeks after end of treatment.
    - Virus breakthrough: HCV RNA decreases during treatment (undetectable levels can be seen), followed by a clinically relevant increase of HCV RNA during treatment.
    - Partial response:> 2 log drop in HCV RNA, but the viral load remains above the lowest measurable level after 12 weeks of treatment.
    - Relapse: negative HCV RNA during treatment but relapse of HCV RNA after treatment is completed.
    - Non-response: no effect of treatment. The patient is persistent HCV RNA positive, despite treatment.
    - Date of birth, sex and ethnicity
    - Country of origin.
    - Previous treatment and treatment response.
    - Hepatitis B and / or HIV infection.
    - Mode of transmission.
    - IL-28B genotype and subtype.
    - Liver fibrosis / cirrhosis status at baseline and liver transplantations status.
    - Start and end dates of treatment, hepatitis C viral load (HCV RNA titers) and alanine transaminase (ALT) levels at baseline and during treatment at weeks 1, 2, 4, 8, 12 and at week 4, 8, 12 after end of treatment.
    - Viral resistance evaluated by population sequencing of the hepatitis C virus genome in patients with treatment failure in Study I.
    - The immune systems response to DAA treatment evaluated by measuring the number of T cells and the amount of antibodies produced by B cells before, during and after treatment for participants enrolled at Copenhagen University Hospital, Hvidovre.
    - A reduction in the degree of inflammation in the liver and macrophage activation determined by the level of sCD163.
    - Change in hepatic venous pressure determined by HVPG
    - Changes in the metabolic liver function determined by GEC.
    - Change in the degree of liver fibrosis measured by Fibroscan.
    - Changes in MELD and Child-Pugh score
    - Changes in the level of liver enzymes, albumin, INR, platelets and
    alpha-fetoprotein.
    - Changes in the levels of renin, aldosterone, copeptin, catecholamines,
    cytokines, hsCRP, hsTNT, pro-ANP, pro-BNP, NGAL and Cystatin C.
    - Changes in WWF-A, WWF-N, D-Dimer, D-fragment, FPA, FXIII, LOXL2, ELM7, LG1M.
    - Change in the perfusion and calcium score assessed by cardiac
    rubidium PET/CT scan.
    Behandlingsrespons defineret som følgende:
    - Vedvarende virologisk respons (SVR): Negativ HCV-RNA 12 uger efter endt behandling.
    - Virus-gennembrud: HCV-RNA falder under behandlingen (umålelige niveauer kan ses), hvorefter der ses en klinisk relevant stigning af HCV-RNA under behandling.
    - Partiel respons: >2 log fald i HCV-RNA, men virus mængde over laveste målelige niveau efter 12 ugers behandling.
    - Relaps: Negativ HCV RNA under behandlingen, men recidiv (forekomst på ny) af HCV RNA efter behandlingen er afsluttet.
    - Non-respons: ingen effekt af behandlingen. Patienten er vedvarende HCV RNA positiv, trods behandling.
    - Fødselsdag, køn og etnicitet.
    - Oprindelsesland.
    - Tidligere behandling og behandlingsrespons.
    - Hepatitis B og/eller HIV infektion.
    - Smittemåde.
    - IL-28B genotype samt subtype.
    - Lever fibrose/cirrose status ved behandlingsstart samt levertransplantations status.
    - Start- samt slut dato for behandling, hepatitis C virus mængde (HCV-RNA titer) og alanintransaminase (ALT) niveau ved behandlingsstart og under behandlingen ved uge 1, 2, 4, 8, 12 samt ved uge 4, 8, 12 efter endt behandling.
    - Viral resistens evalueret ved hjælp af populations sekventering af hepatitis C virus genomet hos patienter i forsøg I med behandlingssvigt.
    - Immunsystemets respons på DAA behandling evalueret ved hjælp af måling af antallet af T-celler samt mængden af antistoffer produceret af B-celler før, under og efter behandlingen hos forsøgsdeltagere inkluderet på Hvidovre Hospital.
    - Ændring i graden af inflammation i leveren og makrofag aktivering bestemt ved niveauet af sCD163.
    - Ændring i portal trykket bestemt ved HVPG
    - Ændring i den metaboliske leverfunktion bestemt ved GEC test.
    - Ændring i graden af lever fibrose målt ved Fibroscanning.
    - Ændringer i MELD og Child-Pugh score
    - Ændringer i niveauet af leverenzymer, albumin, INR, trombocytter og alpha-føtoprotein.
    - Ændringer i niveauet af renin, aldosteron, copeptin, catecholaminer, cytokiner, hsCRP, hsTNT, pro-ANP, pro-BNP, NGAL og Cystatin C
    - Ændringer i niveauet af WWF-A, WWF-N, D-Dimer, D-fragment, FPA, FXIII, LOXL2, ELM7, LG1M.
    - Ændring i perfusion og calciumscore vurderet ved hjælp af hjerte-rubidium PET/CT scanning.
    E.5.2.1Timepoint(s) of evaluation of this end point
    After the last enrolled patient has completed treatment.
    Når alle patienter har afsluttet behandlingen.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVSL
    LVSL
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months8
    E.8.9.1In the Member State concerned days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 100
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 11
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state111
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Expected normal treatment of the condition according to the national Danish guidelines
    Hvis der ikke opnår helbredelse vil patienten blive blive behandlet i henhold til de danske guidelines for behandling af kronisk hepatitis C.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-06-09
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-05-19
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2018-09-20
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2019 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA